Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.
Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Type:
Grant
Filed:
March 30, 2023
Date of Patent:
December 5, 2023
Assignee:
Bausch Health Ireland Limited
Inventors:
Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
Abstract: Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.
Type:
Application
Filed:
June 25, 2021
Publication date:
September 7, 2023
Applicant:
Bausch Health Ireland Limited
Inventors:
Jacob Cole, Brian R. Rohrs, Daniel J. Stein, Robert J. Israel, Ezra R. Lowe
Abstract: The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.
Abstract: The present disclosure is directed to the use of methylnaltrexone or a salt thereof or an ion pair thereof for reducing mortality in a subject suffering from an underlying disease or condition (e.g., advanced illness, cancer, a chronic non-cancer pain, postoperative ileus, or recovery from orthopedic surgery).
Abstract: In one implementation, a system for detecting counterfeit accessories that are consumable, disposable, or otherwise user replaceable is disclosed. The system includes a host controller, a processor, and a computer-readable storage medium that includes instructions. Upon execution by the processor, the instructions cause the system to perform operations. The operations include obtaining an identifier of an accessory, a current value of usage data for the accessory, and a usage digest of the current value from a storage device associated with the accessory. An expected usage digest is generated based on the current value, the identifier, and a host secret. The expected usage digest is compared with the usage digest and the current value with a threshold usage value. The accessory is activated with the host controller responsive to the expected usage digest being identical to the usage digest and the current value satisfying the threshold usage value.
Abstract: Apparatus and methods for delivering coolant to an energy delivery device used to treat tissue with electromagnetic energy. A cooling system includes a pump that is configured to pump a coolant to the energy delivery device.
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
July 26, 2022
Assignee:
Bausch Health Ireland Limited
Inventors:
Craig Robert Bockenstedt, Gregory T. Wing
Abstract: The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
Abstract: Provided herein are compositions comprising an oil-in-water emulsion, wherein the emulsion comprises a liquid oil component; a cross-linked homopolymer based on acrylic acid and/or a cross-linked copolymer of acrylic acid and acrylic acid esters; and water. In some embodiments, the composition is a vehicle for the delivery of an active agent.
Abstract: The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD.
Type:
Application
Filed:
November 18, 2021
Publication date:
June 9, 2022
Applicant:
Bausch Health Ireland Limited
Inventors:
Lorin K. Johnson, XiaoJun Nicole Deng, William J. Jo Siu, Robert J. Israel, Zeev Heimanson
Abstract: Topical pharmaceutical compositions for treating a skin condition or disorder are provided. The topical pharmaceutical compositions can be formulated as lotions containing a therapeutically effective amount of an active agent, such as tretinoin, a viscosity increasing agent, and advantageously small amounts of both a polymeric emulsifier and an oil component. The topical compositions of the present invention are tolerated exceptionally well by subjects to whom the compositions are administered.
Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Type:
Grant
Filed:
September 17, 2021
Date of Patent:
May 3, 2022
Assignee:
Bausch Health Ireland Limited
Inventors:
Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang